Sclerostin / SOST Protein & Antibody

Sclerostin / SOST Protein & Antibody

Sclerostin is a potent inhibitor of bone formation. Sino Biological offers a comprehensive set of tools for Sclerostin related research. We offer recombinant Sclerostin proteins, Sclerostin antibodies for application such as ELISA, WB, IHC, and Sclerostin ORF cDNA clones.

Sclerostin / SOST Protein, Recombinant

Molecule	Species	Description	Cat. No
Sclerostin/SOST	Human	Sclerostin/SOST Protein, Recombinant	10593-H07H
Sclerostin/SOST	Rat	Sclerostin/SOST Protein, Recombinant	80009-R08H

Sclerostin / SOST Antibody

Molecule	Application	Description	Cat. No
Human Sclerostin/SOST	WB, ELISA	Mouse Monoclonal Antibody	10593-MM01
Human Sclerostin/SOST	WB, ELISA	Sclerostin/SOST Antibody, Rabbit MAb	10593-RM03
Human Sclerostin/SOST	ELISA	Rabbit Polyclonal Antibody	10593-RP02
Human Sclerostin/SOST	WB, ELISA	Rabbit Polyclonal Antibody	10593-RP04

Sclerostin / SOST Related Areas

Cancer>>Growth Factor & Receptor>>TGF-beta Superfamily>>BMP Family>>Sclerostin/SOST

Immunology>>Cytokine & Receptor>>TGF-beta Superfamily>>BMP Family>>Sclerostin/SOST

Immunology>>Cytokine & Receptor>>TGF-beta Superfamily>>TGF-beta Superfamily Modulators>>Sclerostin/SOST

Sclerostin / SOST Alternative Names

Sclerostin, SOST, sclerosteosis, VBCH [Homo sapiens]

Sclerostin, Sost, RP23-398F7.2, 5430411E23Rik [Mus musculus]

Sclerostin / SOST Background

Sclerostin, the protein product of the SOST gene, is a potent inhibitor of bone formation. Sclerostin protein is widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days, and was originally identified as an important regulator of bone remodeling, homeostasis, and links bone resorption and bone apposition. Recent studies have revealed that Sclerostin protein inhibits the bone growth probably by binding to the extracellular domain of the Wnt coreceptors LRP5 and LRP6 and disrupting Wnt-induced Frizzled-LRP complex formation.

Sclerostin / SOST Related Studies

1. Bellido T. (2006) Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact. 6(4): 358-9.
2. van Bezooijen RL, et al. (2007) SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn. 236(2): 606-12.